229 related articles for article (PubMed ID: 23650680)
1. [Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].
Gallardo-Rincón D; Cantú-de-León D; Alanís-López P; Alvarez-Avitia MA; Bañuelos-Flores J; Herbert-Núñez GS; Oñate-Ocaña LF; Pérez-Montiel MD; Rodríguez-Trejo A; Ruvalcaba-Limón E; Serrano-Olvera A; Ortega-Rojo A; Cortés-Esteban P; Erazo-Valle A; Gerson-Cwilich R; De-la-Garza-Salazar J; Green-Renner D; León-Rodríguez E; Morales-Vásquez F; Poveda-Velasco A; Aguilar-Ponce JL; Alva-López LF; Alvarado-Aguilar S; Alvarado-Cabrero I; Aquino-Mendoza CA; Aranda-Flores CE; Bandera-Delgado A; Barragán-Curiel E; Barrón-Rodríguez P; Brom-Valladares R; Cabrera-Galeana PA; Calderillo-Ruiz G; Camacho-Gutiérrez S; Capdeville-García D; Cárdenas-Sánchez J; Carlón-Zárate E; Carrillo-Garibaldi O; Castorena-Roji G; Cervantes-Sánchez G; Coronel-Martínez JA; Chanona-Vilchis JG; Díaz-Hernández V; Escudero-de-los Ríos P; Garibay-Cerdenares O; Gómez-García E; Herrera-Montalvo LA; Hinojosa-García LM; Isla-Ortiz D; Jiménez-López J; Lavín-Lozano AJ; Limón-Rodriguez JA; López-Basave HN; López-García SC; Maffuz-Aziz A; Martínez-Cedillo J; Martínez-López DM; Medina-Castro JM; Melo-Martínez C; Méndez-Herrera C; Montalvo-Esquivel G; Morales-Palomares MA; Morán-Mendoza A; Morgan-Villela G; Mota-García A; Muñoz-González DE; Ochoa-Carrillo FJ; Pérez-Amador M; Recinos-Money E; Rivera-Rivera S; Robles Flores JU; Rojas-Castillo E; Rojas-Marín C; Salas-Gonzáles E; Sámano-Nateras L; Santibañez-Andrade M; Santillán-Gómez A; Silva-García A; Silva JA; Solorza-Luna G; Tabarez-Ortiz AR; Talamás-Rohana P; Tirado-Gómez LL; Torres-Lobatón A; Quijano-Castro F
Rev Invest Clin; 2011; 63(6):665-702. PubMed ID: 23650680
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer.
Fruscio R; Ceppi L; Corso S; Galli F; Dell'Anna T; Dell'Orto F; Giuliani D; Garbi A; Chiari S; Mangioni C; Milani R; Floriani I; Colombo N; Bonazzi CM
Br J Cancer; 2016 Sep; 115(6):641-8. PubMed ID: 27537385
[TBL] [Abstract][Full Text] [Related]
3. Management of a suspicious adnexal mass: a clinical practice guideline.
Dodge JE; Covens AL; Lacchetti C; Elit LM; Le T; Devries-Aboud M; Fung-Kee-Fung M;
Curr Oncol; 2012 Aug; 19(4):e244-57. PubMed ID: 22876153
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum.
Dong X; Yuan L; Zou R; Yao L
J Ovarian Res; 2024 Apr; 17(1):85. PubMed ID: 38641834
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery in ovarian cancer.
Pomel C; Jeyarajah A; Oram D; Shepherd J; Milliken D; Dauplat J; Reynolds K
Cancer Imaging; 2007 Dec; 7(1):210-5. PubMed ID: 18083650
[TBL] [Abstract][Full Text] [Related]
6. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N; Sessa C; du Bois A; Ledermann J; McCluggage WG; McNeish I; Morice P; Pignata S; Ray-Coquard I; Vergote I; Baert T; Belaroussi I; Dashora A; Olbrecht S; Planchamp F; Querleu D;
Ann Oncol; 2019 May; 30(5):672-705. PubMed ID: 31046081
[TBL] [Abstract][Full Text] [Related]
7. Extreme Case of Surgical Port Metastasis in Ovarian Cancer.
Kostrzanowski M; Ziółkowski G; Dąbrowski F
Oncology (Williston Park); 2024 Mar; 38(3):110-114. PubMed ID: 38517412
[TBL] [Abstract][Full Text] [Related]
8. Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.
Di Lorenzo G; Ricci G; Severini GM; Romano F; Biffi S
Theranostics; 2018; 8(16):4279-4294. PubMed ID: 30214620
[TBL] [Abstract][Full Text] [Related]
9. Rationale and Methodologic Approach for Assessing Ovarian Cancer Treatment and Gynecologic Oncologist Involvement in the Midwest Region of the United States.
Ng D; Ross W; Traverso-Ortiz M; Rim SH; Wike JM; Moore AR;
J Registry Manag; 2023; 50(3):85-91. PubMed ID: 37941740
[TBL] [Abstract][Full Text] [Related]
10. Major clinical research advances in gynecologic cancer 2008.
Kim K; Choi SC; Ryu SY; Kim JW; Kang SB
J Gynecol Oncol; 2008 Dec; 19(4):209-17. PubMed ID: 19471658
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.
Asangba AE; Chen J; Goergen KM; Larson MC; Oberg AL; Casarin J; Multinu F; Kaufmann SH; Mariani A; Chia N; Walther-Antonio MRS
Sci Rep; 2023 Jan; 13(1):730. PubMed ID: 36639731
[TBL] [Abstract][Full Text] [Related]
12. Major clinical research advances in gynecologic cancer in 2010.
Suh DH; Kim JW; Kim K; Kang SB
J Gynecol Oncol; 2010 Dec; 21(4):209-18. PubMed ID: 21278881
[TBL] [Abstract][Full Text] [Related]
13. Role of tumor microenvironment in ovarian cancer pathobiology.
Ghoneum A; Afify H; Salih Z; Kelly M; Said N
Oncotarget; 2018 Apr; 9(32):22832-22849. PubMed ID: 29854318
[TBL] [Abstract][Full Text] [Related]
14. Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis.
Kwolek DG; Gerstberger S; Tait S; Qiu JM
Med Clin North Am; 2023 Mar; 107(2):329-355. PubMed ID: 36759101
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Version 2.2015.
Gradishar WJ; Anderson BO; Balassanian R; Blair SL; Burstein HJ; Cyr A; Elias AD; Farrar WB; Forero A; Giordano SH; Goetz M; Goldstein LJ; Hudis CA; Isakoff SJ; Marcom PK; Mayer IA; McCormick B; Moran M; Patel SA; Pierce LJ; Reed EC; Salerno KE; Schwartzberg LS; Smith KL; Smith ML; Soliman H; Somlo G; Telli M; Ward JH; Shead DA; Kumar R
J Natl Compr Canc Netw; 2015 Apr; 13(4):448-75. PubMed ID: 25870381
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 Dec; 26(12):2505-6. PubMed ID: 26467471
[No Abstract] [Full Text] [Related]
18. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E; ;
Breast; 2014 Oct; 23(5):489-502. PubMed ID: 25244983
[No Abstract] [Full Text] [Related]
19. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Ann Oncol; 2014 Oct; 25(10):1871-1888. PubMed ID: 25234545
[No Abstract] [Full Text] [Related]
20. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
